A Phase 2 interventional study of pramipexole immediate release (IR) and Placebo in Tourette Syndrome, sponsored by Boehringer Ingelheim. Completed at 16 sites in 2 countries. Open to participants aged 6 Years to 17 Years. Per ClinicalTrials.gov, last updated 2014-05-16.
Sponsored by Boehringer Ingelheim · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 139 studies in Tourette Syndrome with a site in United States — 20 open to participants now, 24 under way, 1 of them phase 3. Tourette Syndrome · United States.
Among the 139 studies in Tourette Syndrome with a site in United States, this one is the 36th largest by enrollment of the 105 interventional ones that give a count, is one of 4 that started in 2008, is one of 26 in phase 2, and was the 27th registered.
240 studies on the registry are indexed under Tourette Syndrome; 40 are open to participants now.
Browse Tourette Syndrome studies →20 of the 139 studies in Tourette Syndrome with a site in United States are open now. Recruiting first, the newest first:
University of Minnesota · Sites in United States
Ages 12–17
University of Minnesota · Sites in United States
Ages 12–21
University of Utah · Sites in United States
Ages 8–17
Vanderbilt University Medical Center · Sites in United States
Ages 11–17 · Healthy volunteers
Boston Children's Hospital · Sites in United States
Ages 0–18
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 33 Tourette Syndrome studies recruiting now, 9 (27%) set no upper age limit and 22 (67%) stop at 75 or younger; 20 take children under 18; 9 take healthy volunteers.
This study: 6 Years to 17 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
139 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 11 · Phase 2 30 · Phase 3 12 · Phase 4 8
First in 1988; this study’s year is marked. 4 started in 2008.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 63 is above the median of 36 across 183 interventional studies indexed under Tourette Syndrome.
Median enrollment 33 across the 105 interventional studies, 90 across the 33 observational. Of the 106 that completed or were terminated, 45 (42%) have results posted.
This tab as a report to print or save as PDF → With an account.
34 of 139 have an industry lead sponsor. The 10 most frequent:
Boehringer Ingelheim is the lead sponsor of 2,305 studies on the registry; 62 are open to participants now.
Of its 169 completed or terminated interventional studies of FDA-regulated products, 123 (73%) have results posted.
Boehringer Ingelheim has 2 studies filed under Tourette Syndrome — fewer than ten, so there is no comparison to draw.
6 of the studies in Tourette Syndrome with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05558566Yale UniversityNeurofeedback From the Supplementary Motor Area for Tourette Syndrome | 2026-12-20 |
| NCT01075672Massachusetts General HospitalOutcomes of Cognitive Behavioral Therapy (CBT) Interventions Provided by Unlicensed Professionals | 2027-01 |
| NCT03914664Vanderbilt University Medical CenterNeural Correlates of Sensory Phenomena in Tourette Syndrome | 2027-02-28 |
| NCT04851678Vanderbilt University Medical CenterLongitudinal Impact of Stressors in Adults With Tourette Syndrome | 2027-03-01 |
| NCT05126888Neurothera Labs Inc.SCI-110 in the Treatment of Tourette Syndrome | 2027-10 |
Add all 6 to your calendar (.ics) → With an account.
Among the 139 studies in Tourette Syndrome with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
A randomized, double-blind, placebo-controlled, flexible dose study to evaluate efficacy and safety of Pramipexole versus placebo for 6 weeks in children (age 6-17) diagnosed with Tourette Disorder according to DSM IV criteria. The primary efficacy measure will be the Total Tic Score (TTS) of the Yale Global Tic Severity Scale (YGTSS) at 6 weeks.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: pramipexole immediate release (IR)
Drug: Placebo
Mean Change From Baseline in Total Tic Score of the Yale Global Tic Severity Scale
Total Tic Score is the sum of ten individual ratings of the impairment due to tics. Each scale ranges from 0 (None/Absent) to 5 (Severe) and total score ranges from 0 to 50. Analysis was adjusted for baseline total tic score and age as linear covariates.
Time frame: baseline 6 weeks
Mean Change From Baseline in Total Tic Score of the Yale Global Tic Severity Scale at Week 1
Total Tic Score is the sum of ten individual ratings of the impairment due to tics. Each scale ranges from 0 (None/Absent) to 5 (Severe) and total score ranges from 0 to 50
Time frame: baseline 1 week
Mean Change From Baseline in Total Tic Score of the Yale Global Tic Severity Scale at Week 2
Total Tic Score is the sum of ten individual ratings of the impairment due to tics. Each scale ranges from 0 (None/Absent) to 5 (Severe) and total score ranges from 0 to 50
Time frame: baseline and 2 weeks
Mean Change From Baseline in Total Tic Score of the Yale Global Tic Severity Scale at Week 3
Total Tic Score is the sum of ten individual ratings of the impairment due to tics. Each scale ranges from 0 (None/Absent) to 5 (Severe) and total score ranges from 0 to 50
Time frame: baseline and 3 weeks
Mean Change From Baseline in Total Tic Score of the Yale Global Tic Severity Scale at Week 4
Total Tic Score is the sum of ten individual ratings of the impairment due to tics. Each scale ranges from 0 (None/Absent) to 5 (Severe) and total score ranges from 0 to 50
Time frame: baseline and 4 weeks
Mean Change From Baseline in Total Score of the Yale Global Tic Severity Scale Due to Motor and Phonic Tics at Week 6
Total Score is a rating of the overall impairment due to motor and phonic tics. The scale ranges from 0 (None) to 50 (Severe)
Time frame: baseline and 6 weeks
Mean Change From Baseline in Total Score of the Yale Global Tic Severity Scale Due to Motor and Phonic Tics at Week 1
Total Score is a rating of the overall impairment due to motor and phonic tics. The scale ranges from 0 (None) to 50 (Severe)
Time frame: baseline 1 week
Mean Change From Baseline in Total Score of the Yale Global Tic Severity Scale Due to Motor and Phonic Tics at Week 2
Total Score is a rating of the overall impairment due to motor and phonic tics. The scale ranges from 0 (None) to 50 (Severe)
Time frame: baseline and 2 weeks
Mean Change From Baseline in Total Score of the Yale Global Tic Severity Scale Due to Motor and Phonic Tics at Week 3
Total Score is a rating of the overall impairment due to motor and phonic tics. The scale ranges from 0 (None) to 50 (Severe)
Time frame: baseline and 3 weeks
Mean Change From Baseline in Total Score of the Yale Global Tic Severity Scale Due to Motor and Phonic Tics at Week 4
Total Score is a rating of the overall impairment due to motor and phonic tics. The scale ranges from 0 (None) to 50 (Severe)
Time frame: baseline 4 weeks
Clinical Global Impressions - Improvement at 1 Week
Overall improvement during the last week compared to baseline ranging from 1 (very much improved), 2 (much improved), to 7 (very much worse). Responder has 'very much' or 'much' improvement. Non responder has less improvement than 'much' improvement.
Time frame: baseline and Week 1
Clinical Global Impressions - Improvement at Week 2
Overall improvement during the last week compared to baseline ranging from 1 (very much improved), 2 (much improved), to 7 (very much worse). Responder has 'very much' or 'much' improvement. Non responder has less improvement than 'much' improvement.
Time frame: baseline and Week 2
Clinical Global Impressions - Improvement at Week 3
Overall improvement during the last week compared to baseline ranging from 1 (very much improved), 2 (much improved), to 7 (very much worse). Responder has 'very much' or 'much' improvement. Non responder has less improvement than 'much' improvement.
Time frame: baseline and Week 3
Clinical Global Impressions - Improvement at Week 4
Overall improvement during the last week compared to baseline ranging from 1 (very much improved), 2 (much improved), to 7 (very much worse). Responder has 'very much' or 'much' improvement. Non responder has less improvement than 'much' improvement.
Time frame: baseline and Week 4
Clinical Global Impressions - Improvement at Week 6
Overall improvement during the last week compared to baseline ranging from 1 (very much improved), 2 (much improved), to 7 (very much worse). Responder has 'very much' or 'much' improvement. Non responder has less improvement than 'much' improvement.
Time frame: baseline and Week 6
Clinical Global Impressions - Severity of Illness at Week 1
Assessment of the overall severity of illness on a scale ranging from 1 (not at all ill) to 7 (the most extremely ill patients). Improved, Unchanged and Worsened responses correspond to changes from baseline of: -2 or less, -1 to +1, and 2 or greater.
Time frame: baseline and Week 1
Clinical Global Impressions - Severity of Illness at Week 2
Assessment of the overall severity of illness on a scale ranging from 1 (not at all ill) to 7 (the most extremely ill patients). Improved, Unchanged and Worsened responses correspond to changes from baseline of: -2 or less, -1 to +1, and 2 or greater.
Time frame: baseline and Week 2
Clinical Global Impressions - Severity of Illness at Week 3
Assessment of the overall severity of illness on a scale ranging from 1 (not at all ill) to 7 (the most extremely ill patients). Improved, Unchanged and Worsened responses correspond to changes from baseline of: -2 or less, -1 to +1, and 2 or greater.
Time frame: baseline and Week 3
Clinical Global Impressions - Severity of Illness at Week 4
Assessment of the overall severity of illness on a scale ranging from 1 (not at all ill) to 7 (the most extremely ill patients). Improved, Unchanged and Worsened responses correspond to changes from baseline of: -2 or less, -1 to +1, and 2 or greater.
Time frame: baseline and Week 4
Clinical Global Impressions - Severity of Illness at Week 6
Assessment of the overall severity of illness on a scale ranging from 1 (not at all ill) to 7 (the most extremely ill patients). Improved, Unchanged and Worsened responses correspond to changes from baseline of: -2 or less, -1 to +1, and 2 or greater.
Time frame: baseline and Week 6
Patient Global Impression at Week 1
Assessment of the change of the patient's overall condition during the last week compared to the patient's condition at baseline on a scale ranging from 1 (very much better) to 7 (very much worse). A responder is defined as having a response of very much (1) or much better (2).
Time frame: baseline and Week 1
Patient Global Impression at Week 2
Assessment of the change of the patient's overall condition during the last week compared to the patient's condition at baseline on a scale ranging from 1 (very much better) to 7 (very much worse). A responder is defined as having a response of very much (1) or much better (2).
Time frame: baseline and Week 2
Patient Global Impression at Week 3
Assessment of the change of the patient's overall condition during the last week compared to the patient's condition at baseline on a scale ranging from 1 (very much better) to 7 (very much worse). A responder is defined as having a response of very much (1) or much better (2).
Time frame: baseline and Week 3
Patient Global Impression at Week 4
Assessment of the change of the patient's overall condition during the last week compared to the patient's condition at baseline on a scale ranging from 1 (very much better) to 7 (very much worse). A responder is defined as having a response of very much (1) or much better (2).
Time frame: baseline and Week 4
Patient Global Impression at Week 6
Assessment of the change of the patient's overall condition during the last week compared to the patient's condition at baseline on a scale ranging from 1 (very much better) to 7 (very much worse). A responder is defined as having a response of very much (1) or much better (2).
Time frame: baseline and Week 6
Clinically Significant Abnormalities in Vital Signs (Orthostatic Reaction and Pulse Rate), and Serum Chemistry.
Time frame: baseline and Week 6
| Milestone | Placebo | Pramipexole |
|---|---|---|
| Started | 20 | 43 |
| Completed | 19 | 39 |
| Not completed | 1 | 4 |
| Withdrew: Adverse event | 1 | 2 |
| Withdrew: Lack of efficacy | 0 | 1 |
| Withdrew: Patient moving out of state | 0 | 1 |
Total Tic Score is the sum of ten individual ratings of the impairment due to tics. Each scale ranges from 0 (None/Absent) to 5 (Severe) and total score ranges from 0 to 50. Analysis was adjusted for baseline total tic score and age as linear covariates.
| score on a scale | Placebo | Pramipexole |
|---|---|---|
| Mean Change From Baseline in Total Tic Score of the Yale Global Tic Severity Scale | -7.17 ± 2.02 | -7.16 ± 1.38 |
Total Tic Score is the sum of ten individual ratings of the impairment due to tics. Each scale ranges from 0 (None/Absent) to 5 (Severe) and total score ranges from 0 to 50
| score on a scale | Placebo | Pramipexole |
|---|---|---|
| Mean Change From Baseline in Total Tic Score of the Yale Global Tic Severity Scale at Week 1 | -3.7 ± 4.1 | -4.1 ± 5.4 |
Total Tic Score is the sum of ten individual ratings of the impairment due to tics. Each scale ranges from 0 (None/Absent) to 5 (Severe) and total score ranges from 0 to 50
| score on a scale | Placebo | Pramipexole |
|---|---|---|
| Mean Change From Baseline in Total Tic Score of the Yale Global Tic Severity Scale at Week 2 | -5.3 ± 7.9 | -5 ± 7.4 |
Total Tic Score is the sum of ten individual ratings of the impairment due to tics. Each scale ranges from 0 (None/Absent) to 5 (Severe) and total score ranges from 0 to 50
| score on a scale | Placebo | Pramipexole |
|---|---|---|
| Mean Change From Baseline in Total Tic Score of the Yale Global Tic Severity Scale at Week 3 | -6.2 ± 6.3 | -5.4 ± 6.3 |
Total Tic Score is the sum of ten individual ratings of the impairment due to tics. Each scale ranges from 0 (None/Absent) to 5 (Severe) and total score ranges from 0 to 50
| score on a scale | Placebo | Pramipexole |
|---|---|---|
| Mean Change From Baseline in Total Tic Score of the Yale Global Tic Severity Scale at Week 4 | -6 ± 7.9 | -6.4 ± 7.3 |
Total Score is a rating of the overall impairment due to motor and phonic tics. The scale ranges from 0 (None) to 50 (Severe)
| score on a scale | Placebo | Pramipexole |
|---|---|---|
| Mean Change From Baseline in Total Score of the Yale Global Tic Severity Scale Due to Motor and Phonic Tics at Week 6 | -15.43 ± 4.44 | -15.58 ± 3.03 |
Total Score is a rating of the overall impairment due to motor and phonic tics. The scale ranges from 0 (None) to 50 (Severe)
| score on a scale | Placebo | Pramipexole |
|---|---|---|
| Mean Change From Baseline in Total Score of the Yale Global Tic Severity Scale Due to Motor and Phonic Tics at Week 1 | -6.2 ± 13.3 | -8.8 ± 11.1 |
Total Score is a rating of the overall impairment due to motor and phonic tics. The scale ranges from 0 (None) to 50 (Severe)
| score on a scale | Placebo | Pramipexole |
|---|---|---|
| Mean Change From Baseline in Total Score of the Yale Global Tic Severity Scale Due to Motor and Phonic Tics at Week 2 | -9.5 ± 16.1 | -10.6 ± 17.5 |
Total Score is a rating of the overall impairment due to motor and phonic tics. The scale ranges from 0 (None) to 50 (Severe)
| score on a scale | Placebo | Pramipexole |
|---|---|---|
| Mean Change From Baseline in Total Score of the Yale Global Tic Severity Scale Due to Motor and Phonic Tics at Week 3 | -14.1 ± 17.2 | -12.2 ± 15.7 |
Total Score is a rating of the overall impairment due to motor and phonic tics. The scale ranges from 0 (None) to 50 (Severe)
| score on a scale | Placebo | Pramipexole |
|---|---|---|
| Mean Change From Baseline in Total Score of the Yale Global Tic Severity Scale Due to Motor and Phonic Tics at Week 4 | -15.5 ± 18.2 | -13.9 ± 15.7 |
Overall improvement during the last week compared to baseline ranging from 1 (very much improved), 2 (much improved), to 7 (very much worse). Responder has 'very much' or 'much' improvement. Non responder has less improvement than 'much' improvement.
| Number of Patients | Placebo | Pramipexole |
|---|---|---|
| Responder | 0 | 5 |
| Not Responder | 20 | 37 |
Overall improvement during the last week compared to baseline ranging from 1 (very much improved), 2 (much improved), to 7 (very much worse). Responder has 'very much' or 'much' improvement. Non responder has less improvement than 'much' improvement.
| Number of Patients | Placebo | Pramipexole |
|---|---|---|
| Responder | 1 | 6 |
| Not Responder | 19 | 36 |
Overall improvement during the last week compared to baseline ranging from 1 (very much improved), 2 (much improved), to 7 (very much worse). Responder has 'very much' or 'much' improvement. Non responder has less improvement than 'much' improvement.
| Number of Patients | Placebo | Pramipexole |
|---|---|---|
| Responder | 2 | 5 |
| Not Responder | 18 | 37 |
Overall improvement during the last week compared to baseline ranging from 1 (very much improved), 2 (much improved), to 7 (very much worse). Responder has 'very much' or 'much' improvement. Non responder has less improvement than 'much' improvement.
| Number of Patients | Placebo | Pramipexole |
|---|---|---|
| Responder | 7 | 6 |
| Not Responder | 13 | 36 |
Overall improvement during the last week compared to baseline ranging from 1 (very much improved), 2 (much improved), to 7 (very much worse). Responder has 'very much' or 'much' improvement. Non responder has less improvement than 'much' improvement.
| Number of Patients | Placebo | Pramipexole |
|---|---|---|
| Responder | 7 | 11 |
| Not Responder | 13 | 31 |
Assessment of the overall severity of illness on a scale ranging from 1 (not at all ill) to 7 (the most extremely ill patients). Improved, Unchanged and Worsened responses correspond to changes from baseline of: -2 or less, -1 to +1, and 2 or greater.
| Number of Patients | Placebo | Pramipexole |
|---|---|---|
| Improved | 0 | 4 |
| Unchanged | 20 | 38 |
| Worsened | 0 | 0 |
Assessment of the overall severity of illness on a scale ranging from 1 (not at all ill) to 7 (the most extremely ill patients). Improved, Unchanged and Worsened responses correspond to changes from baseline of: -2 or less, -1 to +1, and 2 or greater.
| Number of Patients | Placebo | Pramipexole |
|---|---|---|
| Improved | 1 | 4 |
| Unchanged | 19 | 37 |
| Worsened | 0 | 1 |
Assessment of the overall severity of illness on a scale ranging from 1 (not at all ill) to 7 (the most extremely ill patients). Improved, Unchanged and Worsened responses correspond to changes from baseline of: -2 or less, -1 to +1, and 2 or greater.
| Number of Patients | Placebo | Pramipexole |
|---|---|---|
| Improved | 3 | 4 |
| Unchanged | 17 | 37 |
| Worsened | 0 | 1 |
Assessment of the overall severity of illness on a scale ranging from 1 (not at all ill) to 7 (the most extremely ill patients). Improved, Unchanged and Worsened responses correspond to changes from baseline of: -2 or less, -1 to +1, and 2 or greater.
| Number of Patients | Placebo | Pramipexole |
|---|---|---|
| Improved | 4 | 4 |
| Unchanged | 16 | 38 |
| Worsened | 0 | 0 |
Assessment of the overall severity of illness on a scale ranging from 1 (not at all ill) to 7 (the most extremely ill patients). Improved, Unchanged and Worsened responses correspond to changes from baseline of: -2 or less, -1 to +1, and 2 or greater.
| Number of Patients | Placebo | Pramipexole |
|---|---|---|
| Improved | 4 | 10 |
| Unchanged | 16 | 32 |
| Worsened | 0 | 0 |
Assessment of the change of the patient's overall condition during the last week compared to the patient's condition at baseline on a scale ranging from 1 (very much better) to 7 (very much worse). A responder is defined as having a response of very much (1) or much better (2).
| Number of Patients | Placebo | Pramipexole |
|---|---|---|
| Responder | 4 | 7 |
| Not Responder | 16 | 35 |
Assessment of the change of the patient's overall condition during the last week compared to the patient's condition at baseline on a scale ranging from 1 (very much better) to 7 (very much worse). A responder is defined as having a response of very much (1) or much better (2).
| Number of Patients | Placebo | Pramipexole |
|---|---|---|
| Responder | 6 | 9 |
| Not Responder | 14 | 33 |
Assessment of the change of the patient's overall condition during the last week compared to the patient's condition at baseline on a scale ranging from 1 (very much better) to 7 (very much worse). A responder is defined as having a response of very much (1) or much better (2).
| Number of Patients | Placebo | Pramipexole |
|---|---|---|
| Responder | 5 | 7 |
| Not Responder | 15 | 35 |
Assessment of the change of the patient's overall condition during the last week compared to the patient's condition at baseline on a scale ranging from 1 (very much better) to 7 (very much worse). A responder is defined as having a response of very much (1) or much better (2).
| Number of Patients | Placebo | Pramipexole |
|---|---|---|
| Responder | 4 | 7 |
| Not Responder | 16 | 35 |
Assessment of the change of the patient's overall condition during the last week compared to the patient's condition at baseline on a scale ranging from 1 (very much better) to 7 (very much worse). A responder is defined as having a response of very much (1) or much better (2).
| Number of Patients | Placebo | Pramipexole |
|---|---|---|
| Responder | 6 | 12 |
| Not Responder | 14 | 30 |
| participants | Placebo | Pramipexole |
|---|---|---|
| Phosphate - increase | 2 | 5 |
| Bilirubin, total - increase | 0 | 1 |
| Tachycardia | 0 | 1 |
| Orthostatic hypotension | 1 | 4 |
Collected over All events with an onset after the first dose of study medication and up to a period of 48 hours after the last dose of study medication were assigned to the treatment period.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | — | 1/20 (5%) | 13/20 (65%) |
| Pramipexole | — | 0/43 (0%) | 25/43 (58.1%) |
| Event | Placebo | Pramipexole |
|---|---|---|
| Gastroenteritis viralInfections and infestations | 1/20 | 0/43 |
| DehydrationMetabolism and nutrition disorders | 1/20 | 0/43 |
| Event | Placebo | Pramipexole |
|---|---|---|
| HeadacheNervous system disorders | 5/20 | 12/43 |
| NauseaGastrointestinal disorders | 2/20 | 8/43 |
| DizzinessNervous system disorders | 3/20 | 3/43 |
| Oropharyngeal painRespiratory, thoracic and mediastinal disorders | 3/20 | 3/43 |
| VomitingGastrointestinal disorders | 0/20 | 5/43 |
| DiarrhoeaGastrointestinal disorders | 2/20 | 3/43 |
| FatigueGeneral disorders | 2/20 | 4/43 |
| PyrexiaGeneral disorders | 2/20 | 2/43 |
| NasopharyngitisInfections and infestations | 2/20 | 2/43 |
| TicPsychiatric disorders | 2/20 | 1/43 |
| Age, Continuous(Years) | Placebo | Pramipexole | Total |
|---|---|---|---|
| Mean | 11.1 ± 3.2 | 12.2 ± 2.4 | 11.8 ± 2.7 |
| Sex: Female, Male(Participants) | Placebo | Pramipexole | Total |
|---|---|---|---|
| Female | 2 | 8 | 10 |
| Male | 18 | 35 | 53 |
| Attention Deficit Hyperactive Disorder(Number of Patients) | Placebo | Pramipexole | Total |
|---|---|---|---|
| Intermediate | 3 | 6 | 9 |
| Negative | 9 | 22 | 31 |
| Positive | 8 | 15 | 23 |
| Duration of Tourettes syndrome(participants) | Placebo | Pramipexole | Total |
|---|---|---|---|
| 1-5 years | 10 | 19 | 29 |
| Less than 1 years | 6 | 12 | 18 |
| More than 5 years | 4 | 12 | 16 |
| Ethnicity, Customized(Number of Patients) | Placebo | Pramipexole | Total |
|---|---|---|---|
| Hispanic/Latino | 2 | 5 | 7 |
| Not Hispanic/Latino | 18 | 38 | 56 |
| Obsessive Compulsive Disorder(participants) | Placebo | Pramipexole | Total |
|---|---|---|---|
| Intermediate | 1 | 3 | 4 |
| Negative | 16 | 37 | 53 |
| Positive | 3 | 3 | 6 |
| Race, Customized(participants) | Placebo | Pramipexole | Total |
|---|---|---|---|
| Black/African American | 2 | 4 | 6 |
| White | 18 | 39 | 57 |
| Body Mass Index(kilograms/(meters squared)) | Placebo | Pramipexole | Total |
|---|---|---|---|
| Mean | 20.085 ± 5.324 | 22.575 ± 5.656 | 21.784 ± 5.632 |
2 further baseline measures are reported on the registry.
The record gives a start of Jan 2008 and a primary completion of Jun 2009. It does not say whether these dates are actual or estimated.
Results were first posted in Oct 2010, 1 year 4 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.